倩碧控股(08367.HK)控股股東擬配售1.5億股
倩碧控股(08367.HK)公佈,接獲控股股東Marvel Jumbo告知,與東方匯財證券訂立配售協議。
根據配售協議,配售代理同意按盡力基準促使投資者,按配售協議所載的條款並在其條件規限下以相等於或不少於每股配售股份0.12元的價格收購Marvel Jumbo所持有的不多於1.5億股公司現有股份,相當於公司於本公告日期已發行股本總數約15.63%。
完成後,Marvel Jumbo持股由56.25%降至40.63%。
Marvel Jumbo由執行董事兼董事會主席黃雪卿,和執行董事兼公司行政總裁王秀婷控制。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.